Literature DB >> 28592895

Spondyloarthropathies: Targeting IL-17 in refractory PsA.

Jessica McHugh.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28592895     DOI： 10.1038/nrrheum.2017.94

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN： 1759-4790            Impact factor:   20.543


× No keyword cloud information.
  1 in total

1.  Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial.

Authors:  Peter Nash; Bruce Kirkham; Masato Okada; Proton Rahman; Benard Combe; Gerd-Ruediger Burmester; David H Adams; Lisa Kerr; Chin Lee; Catherine L Shuler; Mark Genovese
Journal:  Lancet       Date:  2017-05-24       Impact factor: 79.321
  1 in total
  1 in total

1.  A spontaneous model of spondyloarthropathies that develops bone loss and pathological bone formation: A process regulated by IL27RA-/- and mutant-p53.

Authors:  Denada Dibra; Xueqing Xia; Mihai Gagea; Guillermina Lozano; Shulin Li
Journal:  PLoS One       Date:  2018-03-01       Impact factor: 3.240
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.